We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-2.41%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$3.27B
AUM Growth
+$961M
Cap. Flow
+$1.18B
Cap. Flow %
36.01%
Top 10 Hldgs %
52.28%
Holding
50
New
10
Increased
18
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$156M
2
UHS icon
Universal Health Services
UHS
+$156M
3
CRL icon
Charles River Laboratories
CRL
+$108M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$99.9M
5
GSK icon
GSK
GSK
+$94.8M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$62.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$35.3M
3
INCY icon
Incyte
INCY
+$33.2M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$32.7M
5
EVH icon
Evolent Health
EVH
+$30.7M

Sector Composition

Rank Sector Weight
1 Healthcare 88.38%
2 Technology 1.96%
3 Consumer Discretionary 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNY icon
1
Sanofi
SNY
$107B
$285M 8.73%
7,500,000
+3,500,000
+88% +$156M
VTRS icon
2
Viatris
VTRS
$20.8B
$256M 7.83%
30,000,000
+7,000,000
+30% +$68.9M
UHS icon
3
Universal Health Services
UHS
$10.2B
$198M 6.08%
2,250,000
+1,505,000
+202% +$156M
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.64B
$166M 5.08%
1,500,000
-350,000
-19% -$35.3M
THC icon
5
Tenet Healthcare
THC
$22.2B
$155M 4.74%
3,000,000
+1,350,000
+82% +$80.1M
ZBH icon
6
Zimmer Biomet
ZBH
$18.8B
$146M 4.48%
1,400,000
+50,000
+4% +$5.49M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$140M 4.28%
2,000,000
+1,350,000
+208% +$99.9M
MRK icon
8
CALL
Merck
MRK
$322B
$129M 3.96%
+1,500,000
New +$134M
PTCT icon
9
PTC Therapeutics
PTCT
$6.18B
$123M 3.77%
2,450,000
– –
PFE icon
10
CALL
Pfizer
PFE
$143B
$109M 3.35%
+2,500,000
New +$121M
SEM
11
DELISTED
Select Medical
SEM
$106M 3.25%
8,908,800
+1,484,800
+20% +$21.1M
CRL icon
12
Charles River Laboratories
CRL
$11.3B
$98.4M 3.01%
+500,000
New +$108M
MYGN icon
13
Myriad Genetics
MYGN
$476M
$95.4M 2.92%
5,000,000
– –
PRGO icon
14
Perrigo
PRGO
$1.44B
$89.2M 2.73%
2,500,000
-250,000
-9% -$10M
WBA
15
DELISTED
Walgreens Boots Alliance
WBA
$88.7M 2.72%
2,825,000
– –
IONS icon
16
Ionis Pharmaceuticals
IONS
$8.93B
$85.1M 2.61%
1,925,000
-775,000
-29% -$32.7M
GSK icon
17
GSK
GSK
$107B
$73.6M 2.25%
+2,500,000
New +$94.8M
BKD icon
18
Brookdale Senior Living
BKD
$3.55B
$68.3M 2.09%
16,000,000
– –
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$11.9B
$67.8M 2.08%
800,000
-700,000
-47% -$62.3M
CHNG
20
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$63.9M 1.96%
2,325,000
– –
TEVA icon
21
Teva Pharmaceuticals
TEVA
$40.4B
$60.5M 1.85%
7,500,000
+4,750,000
+173% +$42M
BIIB icon
22
Biogen
BIIB
$30.9B
$53.4M 1.64%
200,000
+75,000
+60% +$15.9M
INCY icon
23
Incyte
INCY
$25.8B
$50M 1.53%
750,000
-450,000
-38% -$33.2M
CANO
24
DELISTED
Cano Health, Inc.
CANO
$43.4M 1.33%
50,000
+20,000
+67% +$12.5M
QDEL icon
25
QuidelOrtho
QDEL
$1.13B
$42.9M 1.31%
+600,000
New +$53.7M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Camber Capital Management held 50 positions worth $3.27B, up 42% from $2.3B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Camber Capital Management deployed $1.18B of net new capital in Q3 2022, opening 10 new positions and adding to 18 existing holdings. Its largest new stake was Charles River Laboratories: 500,000 shares worth $98.4M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 97% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $62.3M trimmed.

  • Camber Capital Management's largest Q3 2022 buy was Charles River Laboratories: 500,000 shares worth $98.4M.
  • Camber Capital Management added most to Sanofi in Q3 2022, an estimated $156M increase.
  • Camber Capital Management's biggest Q3 2022 reduction was BioMarin Pharmaceuticals, cutting an estimated $62.3M.
  • Camber Capital Management fully exited Evolent Health in Q3 2022, selling an estimated $30.7M.
  • Camber Capital Management's ten largest holdings make up 52% of its $3.27B portfolio in Q3 2022.
  • Camber Capital Management opened 10 new positions and closed 5 in Q3 2022.
  • Camber Capital Management's portfolio value rose 42% quarter-over-quarter to $3.27B.

Based on Camber Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.